Risankizumab: Daily Practice Experience of High Need Patients

Psoriasis is a chronic inflammatory disease which affects 29.5 million people worldwide and it can negatively impact quality of life, especially when it affects a special localization, such as nails, face, palms and soles, or intertriginous regions. Risankizumab is a humanized monoclonal antibody wh...

Descripción completa

Detalles Bibliográficos
Autores principales: Brunasso, Alexandra M. G., Burlando, Martina, Amoruso, Fabrizio, Arancio, Luisa, Malara, Giovanna, Manzo, Raffaella, Montesu, Maria Antonia, Caldarola, Giacomo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10296177/
https://www.ncbi.nlm.nih.gov/pubmed/37371864
http://dx.doi.org/10.3390/biomedicines11061769

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10296177/
https://www.ncbi.nlm.nih.gov/pubmed/37371864
http://dx.doi.org/10.3390/biomedicines11061769

Ejemplares similares